DexCom, Inc. (ETR:DC4)
Germany flag Germany · Delayed Price · Currency is EUR
61.48
-1.13 (-1.80%)
At close: Mar 5, 2026

DexCom Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.

The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.

It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc.
Country United States
Founded 1999
Industry Electromedical and Electrotherapeutic Apparatus
Employees 11,100
CEO Jacob Leach

Contact Details

Address:
6340 Sequence Drive
San Diego, California 92121
United States
Phone 858 200 0200
Website dexcom.com

Stock Details

Ticker Symbol DC4
Exchange Deutsche Börse Xetra
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 3845

Key Executives

Name Position
Jacob Leach Chief Executive Officer
Jereme Sylvain Chief Financial Officer
Sean Christensen Head of Investor Relations